Ardent Health Partners, Inc. (ARDT)vsEli Lilly and Company (LLY)
ARDT
Ardent Health Partners, Inc.
$10.93
-4.71%
HEALTHCARE · Cap: $1.50B
LLY
Eli Lilly and Company
$1,155.27
-4.55%
HEALTHCARE · Cap: $1.02T
Smart Verdict
WallStSmart Research — data-driven comparison
Eli Lilly and Company generates 1024% more annual revenue ($72.25B vs $6.43B). LLY leads profitability with a 35.0% profit margin vs 2.1%. ARDT trades at a lower P/E of 11.0x. LLY earns a higher WallStSmart Score of 76/100 (B+).
ARDT
Hold47
out of 100
Grade: D+
LLY
Strong Buy76
out of 100
Grade: B+
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Attractively priced relative to earnings
Reasonable price relative to book value
Mega-cap, among the largest globally
Every $100 of equity generates 81 in profit
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 49.4%
Revenue surging 55.5% year-over-year
Earnings expanding 169.9% YoY
Areas to Watch
Smaller company, higher risk/reward
ROE of 7.7% — below average capital efficiency
2.1% margin — thin
Elevated debt levels
Expensive relative to growth rate
Elevated debt levels
Premium valuation, high expectations priced in
Trading at 33.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARDT
The strongest argument for ARDT centers on P/E Ratio, Price/Book.
Bull Case : LLY
The strongest argument for LLY centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 35.0% and operating margin at 49.4%. Revenue growth of 55.5% demonstrates continued momentum.
Bear Case : ARDT
The primary concerns for ARDT are Market Cap, Return on Equity, Profit Margin. Thin 2.1% margins leave little buffer for downturns.
Bear Case : LLY
The primary concerns for LLY are PEG Ratio, Debt/Equity, P/E Ratio. A P/E of 41.8x leaves little room for execution misses.
Key Dynamics to Monitor
ARDT profiles as a value stock while LLY is a growth play — different risk/reward profiles.
ARDT carries more volatility with a beta of 0.75 — expect wider price swings.
LLY is growing revenue faster at 55.5% — sustainability is the question.
LLY generates stronger free cash flow (3.0B), providing more financial flexibility.
Bottom Line
LLY scores higher overall (76/100 vs 47/100), backed by strong 35.0% margins and 55.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ardent Health Partners, Inc.
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Ardent Health Partners, Inc., headquartered in Nashville, Tennessee, is a prominent healthcare organization dedicated to delivering high-quality, patient-centered care across its extensive network of hospitals and outpatient facilities. With a strong emphasis on innovation and operational excellence, Ardent integrates a diverse array of acute care services and customized healthcare solutions to meet the unique needs of the communities it serves. Backed by a robust financial position and a strategic growth agenda, the company is well-positioned to expand healthcare access and enhance patient outcomes amid the continually evolving healthcare landscape.
Visit Website →Eli Lilly and Company
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Eli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Visit Website →Compare with Other MEDICAL CARE FACILITIES Stocks
Want to dig deeper into these stocks?